Candel therapeutics receives orphan drug designation from the european medicines agency for can-2409 in glioma

Needham, mass., sept. 15, 2022 (globe newswire) -- candel therapeutics, inc. (nasdaq: cadl) (candel or the company), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that the european medicines agency (ema) committee for orphan medical products (comp) has issued a positive opinion on the company's application for orphan drug designation for can-2409 for the treatment of glioma. can-2409, a genetically modified adenovirus and the company's most advanced investigational therapy, is currently being evaluated in multiple phase 2 and phase 3 clinical trials for lung, brain, pancreatic and prostate cancers.
CADL Ratings Summary
CADL Quant Ranking